Recent Posts in ‘Biotech Stock Profiles’
Investing in an Atherosclerotic Plaque Breakthrough
Atherosclerosis is a disease characterized by plaque build-up inside the arteries, which carry oxygen-rich blood to the heart and other parts of the body. The plaque, consisting mostly of fat, cholesterol, calcium, and other substances, hardens over time and narrows these arteries, which can limit oxygen-rich blood flow and lead to heart attack, stroke, or
Advanced Wound Care Made Simple
Demographic trends towards an aging population, soaring diagnosis rates in diabetes, obesity and cardiovascular disease are just a few of the factors that are driving growth and spurring innovation to better serve millions of wound care patients each year. The wound care industry has many verticals for sales, but probably none more critical than diabetic
Diabetes Treatment That Works: Boston Therapeutics (BTHE)
Diabetes. It is everywhere you look, if you have an eye for such things. It is estimated that one dollar out of every ten spent on health care in the United States is related to diabetes. There are currently more than 25 million people in the U.S. with the disease. That number is expected to
Tonix Pharmaceuticals (TNXP): A Low-Risk Biotech with Near-term Catalysts
Fibromyalgia afflicts approximately one in 50 Americans and is the second most common ailment affecting the musculoskeletal system, but the disease has no cure, and the three FDA-approved treatments leave many patients unsatisfied. Although the existing approved and off-label drugs are a $1.4 B US market, they only address some symptoms and not the underlying
OxySure (OXYS) May have Developed the Next AED
Imagine that you’re at a sporting event and someone collapses next to you from a sudden heart attack. If you’re like most Americans, you’ll immediately look for an automated external defibrillator (AED) to jumpstart the person’s heart and save a life. With more than two million units sold so far in the US alone by
Boston Therapeutics (BTHE) is “One to Watch”
The following story is reprinted with permission from MissionIR’s original story here: http://missionir.com/blog/small-cap-news/boston-therapeutics-inc-bthe-is-one-to-watch/ Boston Therapeutics has assembled a team with over six decades of combined experience in complex carbohydrate chemistry and nearly as many decades on the business end of the pharmaceutical industry. The company is able to boast today of a far-reaching applied carbohydrate
AtheroNova Patents Promising Atherosclerosis Drug
AtheroNova, Inc. (OTCBB: AHRO) recently announced the allowance of their patent application for a compound that has shown, in early studies, the ability to actually remove plaque in cases of atherosclerosis. While further studies are needed, the U.S. Patent Office has confirmed the promise of their compound and the intellectual property rights add value to
Boston Therapeutics Builds a Better Metformin Mousetrap
Diabetes is experiencing a heightened awareness with debates in Washington over healthcare costs and pharmaceuticals companies working to develop new therapies for one of the world’s fastest growing diseases. Presently, one in ten people in the United States is diagnosed with diabetes with that ratio expected to mushroom to one in three by the year
September Proves Another Productive Month at Cardium Therapeutics
As in previous months, September was busy again for Cardium Therapeutics (NYSE MKT: CXM) with the company showcasing its portfolio of products and technologies at leading biotechnology investor conferences. Of particular interest during the month included a presentation by Cardium’s Chief Executive Officer and Chairman Christopher Reinhard presented at the BioX Noble Financial Life Sciences
Fluoropharma Medical (FPMI): Potential Breakthroughs in Heart Disease Diagnosis
Imagine that you’re at risk for a heart attack. How would you know? A doctor may give you electrocardiograms (EKG), stress tests or angiograms, but these tests are can be inconclusive or late in diagnosing problems. As a result, you could end up receiving a one-size-fits-all treatment that greatly increases the odds of potential future
Aethlon Could Be Astronaut in MD Anderson Cancer Center Moon Shot Program
On September 21, the cancer research experts at Houston’s MD Anderson Cancer Center announced its “Moon Shot Program” – named in honor of President John F. Kennedy’s bold prediction in 1962 that the U.S. would make it to the moon by the 1970’s – as it embarks on a journey to drastically reduce the number
Accentia Biopharma (ABPI) Appears Undervalued
Accentia Biopharmaceuticals Inc. (OTCQB: ABPI), majority owner of Biovest International Inc. (OTCQB: BVTI) and other subsidiaries, operating in the same space as companies like Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), appears to be an undervalued cancer stock given its extensive clinical backing. Innovative Solution to Unmet Needs Accentia Biopharmaceuticals’ majority-owned